keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer screening

keyword
https://www.readbyqxmd.com/read/28433938/imaging-lysosomal-highly-reactive-oxygen-species-and-lighting-up-cancer-cells-and-tumors-enabled-by-a-si-rhodamine-based-near-infrared-fluorescent-probe
#1
Hongxing Zhang, Jing Liu, Chenlu Liu, Pengcheng Yu, Minjia Sun, Xiaohan Yan, Jian-Ping Guo, Wei Guo
Lysosomes have recently been regarded as the attractive pharmacological targets for selectively killing of cancer cells via lysosomal cell death (LCD) pathway that is closely associated with reactive oxygen species (ROS). However, the details on the ROS-induced LCD of cancer cells are still poorly understood, partially due to the absence of a lysosome-targetable, robust, and biocompatible imaging tool for ROS. In this work, we brought forward a Si-rhodamine-based fluorescent probe, named PSiR, which could selectively and sensitively image the pathologically more relavent highly reactive oxygen species (hROS: HClO, HO, and ONOO(-)) in lysosomes of cancer cells...
April 14, 2017: Biomaterials
https://www.readbyqxmd.com/read/28432840/detection-of-egfr-mutations-in-patients-with-non-small-cell-lung-cancer-by-high-resolution-melting-comparison-with-other-methods
#2
Carlos Martínez-Carretero, Fernando Iguaz Pascual, Antonio Rus, Ivan Bernardo
BACKGROUND: The discovery of mutations in the epidermal growth factor receptor gene (EGFR) related to the clinical response to tyrosine kinase inhibitors, has transformed the management of non-small cell lung cancer (NSCLC). Several methods have been developed for determination of mutations in EGFR, with different sensitivity and potential ability to detect a different number of mutations. METHODS: We developed a screening method by high resolution melting (HRM) to detect EGFR mutations, and compared the results of 123 fixed in formalin and paraffin embedded (FFPE) tumor tissue samples with the detection of mutations by allele-specific PCR...
April 22, 2017: Clinical Chemistry and Laboratory Medicine: CCLM
https://www.readbyqxmd.com/read/28432274/sensitive-detection-of-viable-circulating-tumor-cells-using-a-novel-conditionally-telomerase-selective-replicating-adenovirus-in-non-small-cell-lung-cancer-patients
#3
Shinsaku Togo, Nobuyoshi Katagiri, Yukiko Namba, Miniwan Tulafu, Kumi Nagahama, Kotarou Kadoya, Kazuya Takamochi, Siaki Oh, Kenji Suzuki, Fuminori Sakurai, Hiroyuki Mizuguchi, Yasuo Urata, Kazuhisa Takahashi
Circulating tumor cells (CTCs) have a crucial role in the clinical outcome of cancer patients. Detection of non-small cell lung cancer (NSCLC) using an antibody against epithelial cell adhesion molecule (EpCAM) in captured CTCs has low sensitivity; the loss of epithelial markers leads to underestimation of CTCs with mesenchymal phenotype. We propose a new approach for detection of viable CTCs, including those with epithelial-mesenchymal transition status (EMT-CTCs), using the new telomerase-specific replication-selective adenovirus (OBP-1101), TelomeScan F35...
April 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28429205/comparison-of-digital-tomosynthesis-and-computed-tomography-for-lung-nodule-detection-in-sos-screening-program
#4
Maurizio Grosso, Roberto Priotto, Donatella Ghirardo, Alberto Talenti, Emanuele Roberto, Luca Bertolaccini, Alberto Terzi, Stéphane Chauvie
PURPOSE: To compare the lung nodules' detection of digital tomosynthesis (DTS) and computed tomography (CT) in the context of the SOS (Studio OSservazionale) prospective screening program for lung cancer detection. MATERIALS AND METHODS: One hundred and thirty-two of the 1843 subjects enrolled in the SOS study underwent CT because non-calcified nodules with diameters larger than 5 mm and/or multiple nodules were present in DTS. Two expert radiologists reviewed the exams classifying the nodules based on their radiological appearance and their dimension...
April 20, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/28428185/investments-in-cancer-research-awarded-to-uk-institutions-and-the-global-burden-of-cancer-2000-2013-a-systematic-analysis
#5
Mahiben Maruthappu, Michael G Head, Charlie D Zhou, Barnabas J Gilbert, Majd A El-Harasis, Rosalind Raine, Joseph R Fitchett, Rifat Atun
OBJECTIVES: To systematically categorise cancer research investment awarded to United Kingdom (UK) institutions in the period 2000-2013 and to estimate research investment relative to disease burden as measured by mortality, disability-adjusted life years (DALYs) and years lived with disability (YLDs). DESIGN: Systematic analysis of all open-access data. SETTING AND PARTICIPANTS: Public and philanthropic funding to all UK cancer research institutions, 2000-2013...
April 20, 2017: BMJ Open
https://www.readbyqxmd.com/read/28428148/plasma-ctdna-analysis-for-detection-of-the-egfr-t790m-mutation-in-patients-with-advanced-non-small-cell-lung-cancer
#6
Suzanne Jenkins, James C-H Yang, Suresh S Ramalingam, Karen Yu, Sabina Patel, Susie Weston, Rachel Hodge, Mireille Cantarini, Pasi A Jänne, Tetsuya Mitsudomi, Glenwood D Goss
INTRODUCTION: Tumor biopsies for detecting epidermal growth factor receptor mutations (EGFRm) in advanced non-small cell lung cancer (NSCLC) are invasive, costly and not always feasible for patients with late-stage disease. The clinical utility of the cobas(®) EGFR Mutation Test v2 with plasma samples from patients with NSCLC at disease progression following previous EGFR-tyrosine kinase inhibitor (TKI) therapy was investigated to determine osimertinib treatment eligibility. METHODS: Matched tumor tissue and plasma samples from patients screened for AURA extension and AURA2 phase II studies were tested for EGFRm using tissue- and plasma-based cobas(®) EGFR Mutation Tests v2...
April 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28425241/incidence-of-cancer-in-the-turkish-republic-of-northern-cyprus
#7
Ruqiya Pervaiz, Pınar Tulay, Faisal Faisal, Nedime Serakinci
BACKGROUND/AIM: This study analyzed the incidence, trends, and common types of cancer in the Turkish Republic of Northern Cyprus (TRNC). MATERIALS AND METHODS: This study is based on data collected from the office of the North Cyprus Cancer Registry, Ministry of Health, for 2007-2012. Data were arranged on the basis of age group, sex, and cancer site. Age standardized incidence rates (ASRs) were estimated with the world standard population. EVIEWS (version 9) software was used for statistical analysis...
April 18, 2017: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/28424361/computed-tomographic-findings-in-subjects-who-died-from-respiratory-disease-in-the-national-lung-screening-trial
#8
Esther Pompe, Pim A de Jong, David A Lynch, Nikolas Lessmann, Ivana Išgum, Bram van Ginneken, Jan-Willem J Lammers, Firdaus A A Mohamed Hoesein
We evaluated the prevalence of significant lung abnormalities on computed tomography (CT) in patients who died from a respiratory illness other than lung cancer in the National Lung Screening Trial (NLST).In this retrospective case-control study, NLST participants in the CT arm who died of respiratory illness other than lung cancer were matched for age, sex, pack-years and smoking status to a surviving control. A chest radiologist and a radiology resident blinded to the outcome independently scored baseline CT scans visually and qualitatively for the presence of emphysema, airway wall thickening and fibrotic lung disease...
April 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28423657/identification-and-characterization-of-rassf1c-pirna-target-genes-in-lung-cancer-cells
#9
Mark E Reeves, Mathew Firek, Abdullaati Jliedi, Yousef G Amaar
RASSF1C up-regulates important genes involved in lung cancer cell growth, including a stem cell self-renewal gene, piwil1. In this article, we report the identification of small noncoding PIWI-interacting RNAs (piRNAs) in lung cancer cells over-expressing RASSF1C. A piRNA microarray screen was performed using RNA isolated from the lung cancer cell line H1299 stably over-expressing RASSF1C and corresponding control. The piRNA microarray screen identified several piRNAs that are regulated by RASSF1C and we have validated the expression of two up-regulated piRNAs (piR-34871 and piR-52200) and two down-regulated piRNAs (piR-35127 and piR-46545) in lung cancer cells with silenced and over-expressed RASSF1C using RT-PCR...
March 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28422152/towards-automatic-pulmonary-nodule-management-in-lung-cancer-screening-with-deep-learning
#10
Francesco Ciompi, Kaman Chung, Sarah J van Riel, Arnaud Arindra Adiyoso Setio, Paul K Gerke, Colin Jacobs, Ernst Th Scholten, Cornelia Schaefer-Prokop, Mathilde M W Wille, Alfonso Marchianò, Ugo Pastorino, Mathias Prokop, Bram van Ginneken
The introduction of lung cancer screening programs will produce an unprecedented amount of chest CT scans in the near future, which radiologists will have to read in order to decide on a patient follow-up strategy. According to the current guidelines, the workup of screen-detected nodules strongly relies on nodule size and nodule type. In this paper, we present a deep learning system based on multi-stream multi-scale convolutional networks, which automatically classifies all nodule types relevant for nodule workup...
April 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28421812/the-frequency-of-incidental-findings-and-subsequent-evaluation-in-low-dose-ct-scans-for-lung-cancer-screening
#11
Lillie Morgan, Humberto Choi, Michal Reid, Ali Khawaja, Peter J Mazzone
RATIONALE: The USPSTF recommends lung cancer screening with low-dose chest CT scans (LDCT) for a well-defined high-risk population. Data on the frequency and impact of incidental findings on LDCT scans performed within a centralized lung cancer screening program has not been reported. OBJECTIVES: Previous studies have reported IFs in the setting of clinical trials. We present our findings in a real clinical setting where the decision to manage these findings may depend on factors that are not captured in a research trial such as disclosing IFs, patient preferences, severity of comorbidities, and physician expertise...
April 19, 2017: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/28420097/synthesis-of-curcuminoids-and-evaluation-of-their-cytotoxic-and-antioxidant-properties
#12
María Concepción Lozada-García, Raúl G Enríquez, Teresa O Ramírez-Apán, Antonio Nieto-Camacho, Juan Francisco Palacios-Espinosa, Zeltzin Custodio-Galván, Olivia Soria-Arteche, Jaime Pérez-Villanueva
Curcumin (1) and ten derivatives (2-11) were synthesized and evaluated as cytotoxic and antioxidant agents. The results of primary screening by Sulforhodamine B assay against five human cancer cell lines (U-251 MG, glioblastoma; PC-3, human prostatic; HCT-15, human colorectal; K562, human chronic myelogenous leukemia; and SKLU-1, non-small cell lung cancer) allowed us to calculate the half maximal inhibitory concentration (IC50) values for the more active compounds against HCT-15 and K562 cell lines. Compounds 2 and 10 were the most active against both cell lines and were more active than curcumin itself...
April 14, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28419107/characterization-of-a-transgenic-mouse-model-exhibiting-spontaneous-lung-adenocarcinomas-with-a-metastatic-phenotype
#13
Hsuen-Wen Chang, Zih-Miao Lin, Min-Ju Wu, Li-Yu Wang, Yen-Hung Chow, Shih Sheng Jiang, Hui-Ju Ch'ang, Vincent Hs Chang
Developing lung cancer in mouse models that display similarities of both phenotype and genotype will undoubtedly provide further and better insights into lung tumor biology. Moreover, a high degree of pathophysiological similarity between lung tumors from mouse models and their human counterparts will make it possible to use these mouse models for preclinical tests. Ovine pulmonary adenocarcinomas (OPAs) present the same symptoms as adenocarcinomas in humans and are caused by a betaretrovirus. OPAs have served as an exquisite model of carcinogenesis for human lung adenocarcinomas...
2017: PloS One
https://www.readbyqxmd.com/read/28418914/met-exon-14-mutations-as-targets-in-routine-molecular-analysis-of-primary-sarcomatoid-carcinoma-of-the-lung
#14
Raphaël Saffroy, Vincent Fallet, Nicolas Girard, Julien Mazieres, Denis Moro Sibilot, Sylvie Lantuejoul, Isabelle Rouquette, Françoise Thivolet-Bejui, Thibaut Vieira, Martine Antoine, Jacques Cadranel, Antoinette Lemoine, Marie Wislez
MET exon 14 splicing mutations are new targetable oncogenic drivers reported in 3% of non-small cell lung cancer (NSCLC) cases and have been shown to be more common in pulmonary sarcomatoid carcinomas (PSCs). This study sought to screen mutations affecting MET exon 14 splice sites in a large SC cohort of Caucasian patients, with a large adenocarcinoma cohort as internal control.We tested 81 patients with SC and 150 with adenocarcinoma for splice site DNA mutations leading to RNA splicing-based skipping of MET exon 14...
March 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28416207/reflections-on-the-implementation-of-low-dose-computed-tomography-screening-in-individuals-at-high-risk-of-lung-cancer-in-spain
#15
Pilar Garrido, Marcelo Sánchez, José Belda Sanchis, Nicolás Moreno Mata, Ángel Artal, Ángel Gayete, José María Matilla González, José Marcelo Galbis Caravajal, Dolores Isla, Luis Paz-Ares, Luis M Seijo
Lung cancer (LC) is a major public health issue. Despite recent advances in treatment, primary prevention and early diagnosis are key to reducing the incidence and mortality of this disease. A recent clinical trial demonstrated the efficacy of selective screening by low-dose computed tomography (LDCT) in reducing the risk of both lung cancer mortality and all-cause mortality in high-risk individuals. This article contains the reflections of an expert group on the use of LDCT for early diagnosis of LC in high-risk individuals, and how to evaluate its implementation in Spain...
April 14, 2017: Archivos de Bronconeumología
https://www.readbyqxmd.com/read/28412093/non-small-cell-lung-cancer-as-a-second-primary-among-patients-with-previous-malignancy-who-is-at-risk
#16
Geena X Wu, Rebecca A Nelson, Jae Y Kim, Dan J Raz
BACKGROUND: Patients with previous malignancies could be at increased risk of non-small cell lung cancer (NSCLC). However, the extent of the risk is unknown for many cancer types; thus, it is unclear who might benefit from screening. MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Results data set from 1992 to 2012 was used to identify patients with previous malignancies who received a diagnosis of NSCLC ≥ 6 months after their initial cancer diagnosis...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28410587/overview-of-cancer-incidence-and-mortality-among-people-living-with-hiv-aids-in-british-columbia-canada-implications-for-haart-use-and-nadm-development
#17
Connie G Chiu, Danielle Smith, Kate A Salters, Wendy Zhang, Steve Kanters, David Milan, Julio S G Montaner, Andy Coldman, Robert S Hogg, Sam M Wiseman
BACKGROUND: The objective of this study is to evaluate the incidence of non-AIDS defining malignancies (NADMs) among people living with HIV/AIDS (PLWHA) in British Columbia, focusing on clinical correlates, highly active antiretroviral therapy (HAART) use, and survival, in order to elucidate mechanisms for NADM development. METHODS: A retrospective population based analysis was carried out for individuals with HIV/AIDS that began their treatment between 1996 and 2008...
April 14, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28410210/non-invasive-assessment-of-murine-pd-l1-levels-in-syngeneic-tumor-models-by-nuclear-imaging-with-nanobody-tracers
#18
Katrijn Broos, Marleen Keyaerts, Quentin Lecocq, Dries Renmans, Tham Nguyen, David Escors, Adrian Liston, Geert Raes, Karine Breckpot, Nick Devoogdt
Blockade of the inhibitory PD-1/PD-L1 immune checkpoint axis is a promising cancer treatment. Nonetheless, a significant number of patients and malignancies do not respond to this therapy. To develop a screen for response to PD-1/PD-L1 inhibition, it is critical to develop a non-invasive tool to accurately assess dynamic immune checkpoint expression. Here we evaluated non-invasive SPECT/CT imaging of PD-L1 expression, in murine tumor models with varying PD-L1 expression, using high affinity PD-L1-specific nanobodies (Nbs)...
March 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28408935/socioeconomic-and-racial-ethnic-disparities-in-cancer-mortality-incidence-and-survival-in-the-united-states-1950-2014-over-six-decades-of-changing-patterns-and-widening-inequalities
#19
Gopal K Singh, Ahmedin Jemal
We analyzed socioeconomic and racial/ethnic disparities in US mortality, incidence, and survival rates from all-cancers combined and major cancers from 1950 to 2014. Census-based deprivation indices were linked to national mortality and cancer data for area-based socioeconomic patterns in mortality, incidence, and survival. The National Longitudinal Mortality Study was used to analyze individual-level socioeconomic and racial/ethnic patterns in mortality. Rates, risk-ratios, least squares, log-linear, and Cox regression were used to examine trends and differentials...
2017: Journal of Environmental and Public Health
https://www.readbyqxmd.com/read/28407528/immunotherapy-revolutionises-non-small-cell-lung-cancer-therapy-results-perspectives-and-new-challenges
#20
REVIEW
Etienne Giroux Leprieur, Coraline Dumenil, Catherine Julie, Violaine Giraud, Jennifer Dumoulin, Sylvie Labrune, Thierry Chinet
Immune checkpoint inhibitors (ICIs) are antibodies that target key signalling pathways such as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to improve anti-tumour immune responses. Until recently, nivolumab was the only ICI validated for advanced non-small-cell lung cancer (NSCLC) in a second-line treatment setting. Results from recent phase II and phase III randomised trials testing other ICIs have been presented. In Keynote-024, pembrolizumab, an anti-PD1 antibody, was reported to have great efficacy in the first-line treatment of PDL1 ≥ 50% tumours (30% of screened tumours), with a progression-free survival (PFS, median) of 10...
April 10, 2017: European Journal of Cancer
keyword
keyword
43671
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"